Literature DB >> 18604645

Advantages and disadvantages of GH/IGF-I combination treatment.

J A M J L Janssen1.   

Abstract

Growth hormone (GH) is the primary regulator of insulin-like growth factor-I (IGF-I) production in a wide variety of tissues. There is much overlap in the endocrine, metabolic and anabolic effects of GH and IGF-I but both hormones have divergent effects on glucose metabolism, insulin sensitivity and differentiation of prechondrocytes. Theoretically combined administration of GH and IGF-I may be more effective than GH alone or IGF-I alone. Arguments in favor for this are: 1] Clearance of IGF-I may be markedly altered by the co-administration of GH and this will provide sustained actions of IGF-I. 2] Higher serum IGF-I levels are achieved with a combination treatment of GH and IGF-I than with GH treatment alone or IGF-I alone. In addition, combination therapy may have additive or synergistic effects. 3] The combination GH and IGF-I counteracts disadvantageous effects on glucose metabolism of either GH alone or IGF-I alone. 4] GH may exert direct actions on tissues independently from IGF-I. 5] Combination of GH and IGF-I may be more effective in improving tissue IGF-I levels. The combination therapy of GH and IGF-I might be beneficial in growth retardation, in certain specific subgroups of critically ill or catabolic patients and in the treatment of GH-deficient subjects with the metabolic syndrome and/or manifest diabetes. It is at present unknown whether an optimal balance between safety and efficacy can be achieved with the combination therapy of GH and IGF-I, since this combination has been evaluated in only a small number of patient populations and in studies of a relatively short duration. In addition, a disadvantage may be the financial costs of combination therapy of GH and IGF-I. In conclusion, there are many reasons for believing that administration of the combination therapy of GH and IGF-I could have advantages above GH alone or IGF-I alone. However, determination of whether co-administration of GH and IGF-I indeed is superior to either agent alone awaits further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18604645     DOI: 10.1007/s11154-008-9081-5

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  31 in total

Review 1.  Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations.

Authors:  W H Daughaday; P Rotwein
Journal:  Endocr Rev       Date:  1989-02       Impact factor: 19.871

Review 2.  The somatomedin hypothesis 2007: 50 years later.

Authors:  Solomon A Kaplan; Pinchas Cohen
Journal:  J Clin Endocrinol Metab       Date:  2007-11-06       Impact factor: 5.958

Review 3.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions.

Authors:  S Rajaram; D J Baylink; S Mohan
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

Review 4.  Growth hormone therapy for protein catabolism.

Authors:  R C Jenkins; R J Ross
Journal:  QJM       Date:  1996-11

5.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

Authors:  J M Chan; M J Stampfer; E Giovannucci; P H Gann; J Ma; P Wilkinson; C H Hennekens; M Pollak
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

Review 6.  Nutritional regulation of insulin-like growth factor-I.

Authors:  J M Ketelslegers; D Maiter; M Maes; L E Underwood; J P Thissen
Journal:  Metabolism       Date:  1995-10       Impact factor: 8.694

Review 7.  Formation of 150-kDa binary complexes of insulin-like growth factor binding protein-3 and the acid-labile subunit in vitro and in vivo.

Authors:  C Y Lee; M M Rechler
Journal:  Prog Growth Factor Res       Date:  1995

8.  Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.

Authors:  M A Hussain; O Schmitz; A Mengel; Y Glatz; J S Christiansen; J Zapf; E R Froesch
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

9.  Enhanced body growth in uremic rats treated with IGF-I and growth hormone in combination.

Authors:  S J Hazel; C M Gillespie; R J Moore; R G Clark; K F Jureidini; A A Martin
Journal:  Kidney Int       Date:  1994-07       Impact factor: 10.612

10.  Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.

Authors:  S R Kupfer; L E Underwood; R C Baxter; D R Clemmons
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more
  5 in total

1.  Polymeric ionically conductive composite matrices and electrical stimulation strategies for nerve regeneration: In vitro characterization.

Authors:  Ohan S Manoukian; Scott Stratton; Michael R Arul; Joshua Moskow; Naseem Sardashti; Xiaojun Yu; Swetha Rudraiah; Sangamesh G Kumbar
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2018-11-12       Impact factor: 3.368

2.  Muscle-specific growth hormone receptor (GHR) overexpression induces hyperplasia but not hypertrophy in transgenic zebrafish.

Authors:  Marcio Azevedo Figueiredo; Edson A Mareco; Maeli Dal Pai Silva; Luis Fernando Marins
Journal:  Transgenic Res       Date:  2011-08-24       Impact factor: 2.788

Review 3.  Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.

Authors:  Eduardo I Gus; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Burns       Date:  2019-12-15       Impact factor: 2.744

4.  Skeletal response of male mice to anabolic hormone therapy in the absence of the Igfals gene.

Authors:  Oran D Kennedy; Hui Sun; Yingjie Wu; Hayden-William Courtland; Garry A Williams; Luis Cardoso; Jelena Basta-Pljakic; Mitchell B Schaffler; Shoshana Yakar
Journal:  Endocrinology       Date:  2014-01-01       Impact factor: 4.736

5.  In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life.

Authors:  A J Varewijck; A J van der Lely; S J C M M Neggers; S W J Lamberts; L J Hofland; J A M J L Janssen
Journal:  Endocr Connect       Date:  2014-04-15       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.